多发性骨髓瘤治疗的演进或革命及英国的角色
本文综述多发性骨髓瘤(MM)疾病生物学与治疗格局的快速扩展,指出生存改善已在临床试验和真实世界中出现,并以时间脉络举例说明英国临床医生、科研人员及患者和家属在这一变革中的核心作用。
要点
- MM疾病生物学与治疗选择近年呈指数级扩展
- 生存改善已在临床试验与真实世界环境中得到体现
- 英国临床医生、科学家及患者群体在MM治疗变革中发挥核心作用
核心结论
- MM疾病知识与治疗格局快速扩展,生存改善在临床试验和真实世界均有体现,且这一趋势预计将持续。
研究设计与样本
- 本文为非全面性综述,以时间脉络和示例性案例梳理MM治疗发展,并强调英国相关群体的核心作用。
主要发现
- MM疾病生物学与治疗领域的知识呈指数级扩展,生存改善不仅见于临床试验,也见于真实世界环境。
临床怎么用
- 临床应关注MM治疗格局的持续演进,并重视真实世界中的生存改善证据。
局限性
- 本文非全面性综述,旨在提供时间脉络与示例,未系统汇总全部证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The knowledge of disease biology as well as the therapeutic landscape in multiple myeloma (MM) has expanded exponentially in recent years. These advances have seen improvements in survivorship, not only in the clinical trial setting but also in the real setting. Importantly there is also every evidence to indicate that such improvements in our understanding and treatments will continue. This article is not intended to be a comprehensive review; rather it aims to give a temporal context to these developments with exemplars, and highlight the central role that UK clinicians, healthcare workers, scientists and most importantly patients and their relatives have played in this revolution.
引用
- Cook G, Morris CTCM. Evolution or revolution in multiple myeloma therapy and the role of the UK. Br J Haematol. 2020. PMID: 33190259. doi:10.1111/bjh.17148
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。